搜尋結果
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for ...
Bastillepost· 6 日前... (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus ... ...
U.S. FDA approves ImmunityBio's bladder cancer therapy
Reuters· 6 日前, opens new tab combination therapy to treat a type of bladder cancer, marking an end to the ...